<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35522372</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4604</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical pharmacology</Title>
          <ISOAbbreviation>J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcph.2067</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Khiali</LastName>
            <ForeName>Sajad</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Department of Clinical Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Entezari-Maleki</LastName>
            <ForeName>Taher</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-3653-3653</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Department of Clinical Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>0366372</NlmUniqueID>
        <ISSNLinking>0091-2700</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">antivirals</Keyword>
        <Keyword MajorTopicYN="N">molnupiravir</Keyword>
        <Keyword MajorTopicYN="N">nirmatrelvir</Keyword>
        <Keyword MajorTopicYN="N">omicron</Keyword>
        <Keyword MajorTopicYN="N">remdesivir</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>11</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35522372</ArticleId>
        <ArticleId IdType="doi">10.1002/jcph.2067</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>WHO. Update on Omicron. https://www.who.int/news/item/28-11-2021-update-on-omicron. Accessed February 18, 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med. 2022;386(5):492-494.</Citation>
        </Reference>
        <Reference>
          <Citation>Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532-46.</Citation>
        </Reference>
        <Reference>
          <Citation>National Institutes of Health. COVID-19 Treatment Guidelines. Food and Drug Administration; 2022. https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/. Updated January 19, 2022. Accessed February 18, 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671-675.</Citation>
        </Reference>
        <Reference>
          <Citation>Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602:664-670.</Citation>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant. Food and Drug Administration; 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains. Accessed February 18, 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252.</Citation>
        </Reference>
        <Reference>
          <Citation>Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386(4):305-315.</Citation>
        </Reference>
        <Reference>
          <Citation>Good SS, Westover J, Jung KH, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021;65(4):e02479-20.</Citation>
        </Reference>
        <Reference>
          <Citation>Ledford H. The next variant: three key questions about what's after omicron. Nature. 2022;603(7900):212-213.</Citation>
        </Reference>
        <Reference>
          <Citation>Martinez MA. Plitidepsin: a repurposed drug for the treatment of COVID-19. Antimicrob Agents Chemother. 2021;65(4):e00200-e00221.</Citation>
        </Reference>
        <Reference>
          <Citation>Ghanian S, Wambier CG. Letter to the Editor re: Baldassarri et al., 2021 “Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males”. EBioMedicine. 2021;68:103425.</Citation>
        </Reference>
        <Reference>
          <Citation>Baranov MV, Bianchi F, van den Bogaart G. The PIKfyve inhibitor apilimod: a double-edged sword against COVID-19. Cells. 2020;10(1):30.</Citation>
        </Reference>
        <Reference>
          <Citation>Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113-119</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
